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Hepatitis B is an infectious disease with serious health im-
plications caused by hepatitis B virus. With blood, iatro-
genic, sexual and mother-to-fetus transmission as its main 
transmission routes, hepatitis B virus causes diseases in-
cluding acute or chronic hepatitis, liver cirrhosis and liver 
cancer. Most adults infected with hepatitis B virus can be 
healed, while infected infants may typically live with a 
chronic and persistent infection. According to the national 
survey of hepatitis B epidemics conducted in 1979, among 
all surveyed people, the mean carrier rate of hepatitis B 
surface antigen (HBsAg) was 9.76% and that children may 
reach or approximate the peak value when they are only 
four years old. According to a similar survey conducted in 
1992, the mean carrier rate of HBsAg was 9.75%, while for 
children, the peak of HBsAg-carrying rate was slightly re-
duced and delayed, indicating that the epidemic pattern has 
not changed much during 13 years. However, vaccination 
with hepatitis B vaccine in children initiated at the end of 
the 1980s has achieved a beneficial effect [1]. According to 
the national survey conducted in 2004, the HBsAg-carrier 
rate of adults was 7.18%, and the mean carrier rate of chil-
dren (1–4 years old) was reduced to 0.96%, suggesting that 
hepatitis B vaccination, which was widely implemented in 
the 1990s and incorporated into the immunization program 
in 2002, has achieved positive effects [2]. There is no doubt 
that it will continue to contribute to eliminating the harm-
fulness of hepatitis B to people’s health, as long as the hep-
atitis B vaccine program is adhered to.          
The hepatitis B vaccine is widely used in China since its 
successful development using blood resources in 1986. 
Particularly, hepatitis B vaccines based on genetic engi-
neering of CHO cells and yeast cells (introduced by the 
technical department of MERK) were introduced to the 
market in China in 1992 and 1996, respectively. China 
promoted the replacement of blood resource hepatitis B 
vaccines with hepatitis B vaccines based on energetic engi-
neering in 2000 and the incorporation of hepatitis vaccines 
into the program of immunization vaccination in 2002. The 
hepatitis B vaccine based on energetic engineering currently 
uses two cell types: (i) yeast (made in China or imported) 
and (ii) mammalian cells. The hepatitis B vaccine based on 
genetic engineering of yeasts (made in China) has been 
dominantly used for immunization vaccination [3]. With a 
high annual manufacturing quantity (under approval), of 
100 million to 200 million dosages, the hepatitis B vaccine 
based on genetic engineering has been manufactured and 
administered for 20 years in China. Furthermore, it has been 
used as a preventative vaccination for at least 200 million 
infants, from which a large quantity of practical data and 
experience has been accumulated. Therefore, in general, the 
hepatitis B vaccine just mentioned is characterized by ad-
vanced techniques, stable processes and controllable quality 
and is safe and effective. 
The event that “several infants are dead owing to the use 
of hepatitis B vaccine manufactured by Kangtai Company” 
is a serious issue that has provoked a reflection regarding 
the underlying issue of vaccination management (the issue 
related to the quality of the Kangtai vaccine is excluded in 
this paper as it is waiting to be examined by the corre-
sponding drug supervision department). One distinctive 
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feature of the event is that it was first reported by the civil 
media, and the official response only occurred one week 
after the death cases reported increased from 2 to 7 [4]. This 
has caused discussion regarding the use of preventative 
vaccination and the influence of the event is now far beyond 
that of the event itself. Undoubtedly, it is now necessary and 
urgent for us to think about the underlying issues of preven-
tion vaccination. 
First, this event demonstrates that the Chinese vaccine 
adverse reaction monitoring and reporting system is incom-
plete and therefore it is necessary to revise the reporting 
system to enhance accurate monitoring, sensitive reactions 
and timely handling, so that we can react quickly when ad-
verse reactions occur, whether the vaccine is new or old. 
This action should be faster, more accurate, more scientific 
and more powerful than the private media. 
Second, it is necessary to set up a database of vaccination 
adverse reactions. Statements should be made on the basis 
of science to handle adverse events properly. In China, there 
are more than 30 kinds of vaccines, and a database of vac-
cination adverse reactions can provide data support for de-
ciding and handling adverse reactions. For example, hun-
dreds of millions of hepatitis B vaccinations have been 
produced and hundreds of millions of people have been 
vaccinated. If these are produced to a certain scientific 
product quality and a database of vaccination adverse reac- 
tions is established then when a problem occurs, a reasona- 
ble scientific explanation may be given to the public from 
both the company and government.  
Third, it is an important guarantee to setup a compensa-
tion system for serious vaccine adverse reactions. This 
compensation system should be included in the informed 
consent of individuals being vaccinated.  
Finally, with the improvement of living standards, hy-
giene standards and health care standards, the hepatitis B 
plan immunization program can also be altered on a re-
search basis. For example, we should consider whether the 
provision that infants must receive a hepatitis B vaccine 
within 24 h after being born need to be changed. However, 
infants who are hepatitis B surface antigen and/or E antigen 
positive must receive hepatitis B vaccine within 24 h after 
being born.   
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